시장보고서

상품코드

1771594

미국의 고분자 Drug Discovery 아웃소싱 시장 규모, 점유율, 동향 분석 보고서 : 워크플로우별, 서비스별, 치료제 분야별, 최종 용도별, 부문별 예측(2025-2033년)

U.S. Large Molecule Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Workflow (Target Identification & Screening), By Service, By Therapeutics Area (Ophthalmology, Hematology), By End-use, And Segment Forecasts, 2025 - 2033

발행일: 2025년 06월 | 리서치사:

Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

시장 규모와 동향:

미국의 고분자 Drug Discovery 아웃소싱 시장 규모는 2024년 9억 6,860만 달러로 추정되며, 2025년부터 2033년까지 CAGR 9.20%로 성장할 것으로 예상됩니다.

이 시장은 제약 업계의 혁신적 생물학적 제제로의 전환이 가속화되고 생물학적 제제 파이프라인이 확대됨에 따라 강력한 성장세를 보이고 있습니다. 또한 단클론항체, 이중특이성항체, 융합단백질, 항체약물접합체(ADC) 등의 고분자는 암, 자가면역질환, 만성질환 등 다양한 질환의 치료제로서 수요가 지속적으로 증가하고 있습니다.

미국에서는 제약사 및 바이오텍 기업들이 신약개발 프로세스 가속화, 비용 절감, 전문 기술 접근을 위해 CRO(임상시험수탁기관)를 활용하는 사례가 증가하고 있습니다. 이러한 아웃소싱 파트너십은 후보물질 발굴, 후보물질 최적화, 생물학적 서비스, 전임상 개발 등 다양한 서비스를 제공하고 있으며, 통합된 플랫폼 기반 아웃소싱 모델로 전환하고 있습니다. 또한, 생물학적 제제, 특히 융합 단백질 및 인공 항체와 같은 차세대 포맷에 대한 수요가 증가함에 따라 기업들은 사이클 타임 단축과 복잡성 관리를 위해 탐색 업무를 아웃소싱하고 있습니다.

정밀 스크리닝, 표적 생물학, in vitro 기능 분석에 중점을 둔 아웃소싱은 분자 최적화 및 초기 제조 가능성 평가를 강화합니다. 희귀질환 및 맞춤 면역치료와 같은 틈새 치료 영역의 부상으로 고도로 맞춤화된 신약개발 솔루션에 대한 필요성이 더욱 커지고 있습니다. 또한, 단일 파트너 네트워크를 통해 탐색, 전임상, 초기 개발 활동을 통합하는 아웃소싱 모델이 예상 기간 동안 시장을 주도할 것으로 예상됩니다. 미국에서는 AI를 활용한 표적 탐색, 미세유체 기반 스크리닝, 극저온 전자현미경, 클라우드 네이티브 플랫폼과 같은 기술적 진보에 초점을 맞추고 있으며, 광범위한 분자 신약개발 아웃소싱은 다양한 개발 프로그램에 걸친 생물학적 제약 신약개발의 전략적 실현을 위한 다양한 개발 프로그램 전반에 걸친 생물학적 제약 신약개발의 전략적 실현에 기여하고 있으며, 시장 성장을 더욱 촉진하고 있습니다.

미국의 고분자 Drug Discovery 아웃소싱 시장(워크플로우별) : 부문 대시보드
미국의 고분자 Drug Discovery 아웃소싱 시장, 워크플로우별 : 변동 분석
워크플로우별, 2021-2033년
타겟 특정과 스크리닝
타겟 검증과 기능 정보과학
리드 특정과 후보자 최적화
전임상 개발
기타

제5장 미국의 고분자 Drug Discovery 아웃소싱 시장 : 서비스 추정·동향 분석

미국의 고분자 Drug Discovery 아웃소싱 시장(서비스별) : 부문 대시보드
미국의 고분자 Drug Discovery 아웃소싱 시장, 서비스별 : 변동 분석
서비스별, 2021-2033년
화학 서비스
생물학 서비스

제6장 미국의 고분자 Drug Discovery 아웃소싱 시장 : 치료제 분야 추정·동향 분석

미국의 고분자 Drug Discovery 아웃소싱 시장(치료제 분야별) : 부문 대시보드
미국의 고분자 Drug Discovery 아웃소싱 시장, 치료제 분야별 : 변동 분석
치료제 분야별, 2021-2033년
호흡기계
통증과 마취
종양학
안과
혈액학
심혈관계
내분비
위장
면역조절
항감염성
중추신경계
피부과
비뇨생식기계

제7장 미국의 고분자 Drug Discovery 아웃소싱 시장 : 최종 용도 추정·동향 분석

미국의 고분자 Drug Discovery 아웃소싱 시장(최종 용도별) : 부문 대시보드
미국의 고분자 Drug Discovery 아웃소싱 시장, 최종 용도별 : 변동 분석
용도별, 2021-2033년
제약·바이오테크놀러지 기업
학술기관

제8장 경쟁 구도

시장 진입 기업 분류
- 시장 리더
- 신흥 기업
기업 시장 점유율/평가 분석, 2024년
기업 개요
- Charles River Laboratories International, Inc.
- Laboratory Corporation of America Holdings
- Thermo Fisher Scientific, Inc.
- GenScript Biotech Corporation
- Syngene International Limited
- Dalton Pharma Services
- Eurofins Scientific SE
- TCG Lifesciences Pvt Ltd.
- Evotec SE
- WuXi AppTec
- Jubilant Biosys Limited
- Pharmaron Beijing Co., Ltd.

제9장 주요 추천사항

ksm 25.07.24

Market Size & Trends:

The U.S. large molecule drug discovery outsourcing market size was estimated at USD 968.60 million in 2024 and is projected to grow at a CAGR of 9.20% from 2025 to 2033. The market is experiencing robust growth, driven by the accelerating shift in the pharmaceutical industry towards innovative biologics and expanding pipeline biologics. Besides, large molecules, including monoclonal antibodies, bispecific, fusion proteins, and antibody-drug conjugates (ADCs), continue to witness rising demand to treat various diseases, including cancer, autoimmune disorders, and chronic conditions.

In the U.S., pharmaceutical and biotechnology companies are increasingly turning to contract research organizations (CROs) to accelerate the discovery process, lower costs, and gain access to specialized technologies. These outsourcing partnerships provide various services, including lead identification, candidate optimization, biology services, and preclinical development, with a shift toward integrated, platform-based outsourcing models. Moreover, rising demand for biologics, particularly next-generation formats such as fusion proteins and engineered antibodies, has led companies to outsource discovery tasks to reduce cycle times and manage complexity.

Outsourcing the company's focus on precision screening, target biology, and in vitro functional analysis enhances molecular optimization and early manufacturability assessments. The rise of niche therapeutic areas, such as rare diseases and personalized immunotherapies, further increases the need for highly customized discovery solutions. Besides, integrated outsourcing models that combine discovery, preclinical, and early development activities through a single partner network are expected to drive the market over the estimated period. With a focus on technological advancements in the U.S., including AI-driven target discovery, microfluidics-based screening, cryo-electron microscopy, and cloud-native platforms, outsourcing for extensive molecule drug discovery is becoming a strategic enabler of biologic drug discovery across diverse development programs, which further supports the market growth.

U.S. Large Molecule Drug Discovery Outsourcing Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. large molecule drug discovery outsourcing market report based on workflow, service, therapeutics area, and end-use:

Workflow Outlook (Revenue, USD Million, 2021 - 2033)
Target Identification & Screening
Target Validation & Functional Informatics
Lead Identification & Candidate Optimization
Preclinical Development
Others
Service Outlook (Revenue, USD Million, 2021 - 2033)
Chemistry Services
Biology Services
Therapeutics Area Outlook (Revenue, USD Million, 2021 - 2033)
Respiratory system
Pain and Anesthesia
Oncology
Ophthalmology
Hematology
End-use Outlook (Revenue, USD Million, 2021 - 2033)
Pharmaceutical & Biotechnology companies
Academic Institutes

Chapter 1. Research Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
1.5. Information Or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity Flow Analysis
- 1.7.2. Parent Market Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. U.S. Large Molecule Drug Discovery Outsourcing Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Market Analysis Tools
- 3.5.1. Porter's Five Force Analysis
- 3.5.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Large Molecule Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

4.1. U.S. Large Molecule Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
4.2. U.S. Large Molecule Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
4.3. U.S. Large Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2021-2033 (USD Million)
4.4. Target Identification & Screening
- 4.4.1. Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Target Validation & Functional Informatics
- 4.5.1. Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Lead Identification & Candidate Optimization
- 4.6.1. Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Preclinical Development
- 4.7.1. Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Others
- 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Large Molecule Drug Discovery Outsourcing Market: Service Estimates & Trend Analysis

5.1. U.S. Large Molecule Drug Discovery Outsourcing Market, By Service: Segment Dashboard
5.2. U.S. Large Molecule Drug Discovery Outsourcing Market, By Service: Movement Analysis
5.3. U.S. Large Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Service, 2021-2033 (USD Million)
5.4. Chemistry Services
- 5.4.1. Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Biology Services
- 5.5.1. Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Large Molecule Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

6.1. U.S. Large Molecule Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
6.2. U.S. Large Molecule Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
6.3. U.S. Large Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics Area, 2021-2033 (USD Million)
6.4. Respiratory system
- 6.4.1. Respiratory System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Pain and Anesthesia
- 6.5.1. Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Oncology
- 6.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Ophthalmology
- 6.7.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Hematology
- 6.8.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.9. Cardiovascular
- 6.9.1. Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.10. Endocrine
- 6.10.1. Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.11. Gastrointestinal
- 6.11.1. Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.12. Immunomodulation
- 6.12.1. Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.13. Anti-infective
- 6.13.1. Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.14. Central Nervous System
- 6.14.1. Central Nervous System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.15. Dermatology
- 6.15.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.16. Genitourinary System
- 6.16.1. Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Large Molecule Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

7.1. U.S. Large Molecule Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
7.2. U.S. Large Molecule Drug Discovery Outsourcing Market, By End Use: Movement Analysis
7.3. U.S. Large Molecule Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2021-2033 (USD Million)
7.4. Pharmaceutical & Biotechnology companies
- 7.4.1. Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Academic Institutes
- 7.5.1. Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Market Participant Categorization
- 8.1.1. Market Leaders
- 8.1.2. Emerging Players
8.2. Company Market Share/Assessment Analysis, 2024
8.3. Company Profiles
- 8.3.1. Charles River Laboratories International, Inc.
  - 8.3.1.1. Company Overview
  - 8.3.1.2. Financial Performance
  - 8.3.1.3. Service Benchmarking
  - 8.3.1.4. Strategic Initiatives
- 8.3.2. Laboratory Corporation of America Holdings
  - 8.3.2.1. Company Overview
  - 8.3.2.2. Financial Performance
  - 8.3.2.3. Service Benchmarking
  - 8.3.2.4. Strategic Initiatives
- 8.3.3. Thermo Fisher Scientific, Inc.
  - 8.3.3.1. Company Overview
  - 8.3.3.2. Financial Performance
  - 8.3.3.3. Service Benchmarking
  - 8.3.3.4. Strategic Initiatives
- 8.3.4. GenScript Biotech Corporation
  - 8.3.4.1. Company Overview
  - 8.3.4.2. Financial Performance
  - 8.3.4.3. Service Benchmarking
  - 8.3.4.4. Strategic Initiatives
- 8.3.5. Syngene International Limited
  - 8.3.5.1. Company Overview
  - 8.3.5.2. Financial Performance
  - 8.3.5.3. Service Benchmarking
  - 8.3.5.4. Strategic Initiatives
- 8.3.6. Dalton Pharma Services
  - 8.3.6.1. Company Overview
  - 8.3.6.2. Financial Performance
  - 8.3.6.3. Service Benchmarking
  - 8.3.6.4. Strategic Initiatives
- 8.3.7. Eurofins Scientific SE
  - 8.3.7.1. Company Overview
  - 8.3.7.2. Financial Performance
  - 8.3.7.3. Service Benchmarking
  - 8.3.7.4. Strategic Initiatives
- 8.3.8. TCG Lifesciences Pvt Ltd.
  - 8.3.8.1. Company Overview
  - 8.3.8.2. Financial Performance
  - 8.3.8.3. Service Benchmarking
  - 8.3.8.4. Strategic Initiatives
- 8.3.9. Evotec SE
  - 8.3.9.1. Company Overview
  - 8.3.9.2. Financial Performance
  - 8.3.9.3. Service Benchmarking
  - 8.3.9.4. Strategic Initiatives
- 8.3.10. WuXi AppTec
  - 8.3.10.1. Company Overview
  - 8.3.10.2. Financial Performance
  - 8.3.10.3. Service Benchmarking
  - 8.3.10.4. Strategic Initiatives
- 8.3.11. Jubilant Biosys Limited
  - 8.3.11.1. Company Overview
  - 8.3.11.2. Financial Performance
  - 8.3.11.3. Service Benchmarking
  - 8.3.11.4. Strategic Initiatives
- 8.3.12. Pharmaron Beijing Co., Ltd.
  - 8.3.12.1. Company Overview
  - 8.3.12.2. Financial Performance
  - 8.3.12.3. Service Benchmarking
  - 8.3.12.4. Strategic Initiatives